Advancis Pharmaceutical Corp. reported net loss for the first quarter at $7.6 million, narrower than $11.4 million in the year-ago quarter. On a per share basis, loss for the current quarter narrowed to $0.25 from $0.50 in the same quarter last year. Analysts polled by First Call/Thomson Financial expected a loss of $0.29 per share. Trading Markets (http://www.tradingmarkets.com/tm.site/news/BREAKING%20NEWS/241716/)
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
Kleresca Approved in EU for Dermatological Platform
The treatment does not damage the skin’s natural barriers.
Pro-Kratom Nonprofit Pushes Back on Deaths FDA Attributed to Substance
The FDA issued warning letters in May to three U.S. distributors of more than 65 kratom products for sales of unapproved new drugs claiming effectiveness in treating opioid addiction and withdrawal.